Sponsored Links

Newborns caught whooping cough from hospital nurse

Thu Jun 5, 2008 6:59pm EDT
 
[-] Text [+]

NEW YORK (Reuters Health) - Public health officials investigating a 2004 outbreak of whooping cough, or pertussis, among newborns in Texas identified the source as a health-care worker where the babies were born.

Staff members at a children's hospital in Texas noticed that six infants admitted with whooping cough had been born during the first half of June at the same general hospital.

A review of records uncovered a total of 11 such infants, on average about a month old, whose symptoms included cough, congestion, vomiting and arrested breathing. Nine infants had to be admitted to the hospital, including five treated in the intensive care unit.

According to their report in the Morbidity and Mortality Weekly Report, published by the Centers for Disease Control and Prevention, J. L. Hood and colleagues identified a 24-year-old health-care worker who had symptoms of cough, which brought on vomiting, and difficulty breathing while working in the newborn nursery from early June until mid July.

During that time she directly cared for 113 infants, including the 11 who came down with whooping cough.

All the babies recovered after treatment.

The health-care worker in this case had been fully immunized against pertussis during childhood. However, the CDC points out in an editorial note that the Advisory Committee on Immunization Practices recommends that health-care workers with direct patient contact and adults who have close contact with infants should be given the Tdap (tetanus toxoid, reduced diphtheria toxoid and acellular pertussis) vaccine.

SOURCE: Morbidity and Mortality Weekly Report, June 6, 2008.

 

Editor's Choice

A selection of our best photos from the past 24 hours.  Slideshow 

Most Popular on Reuters

  • Articles
  • Video
A customer shops for medicine at a Portland, Oregon drugstore July 31, 2005. REUTERS/Richard Clement RC/YH
Blame game slows growth of personalized medicine

Expectation has been building for a decade that an era of personalized medicine will transform the global drugs business, but the reality is a slow start and an angry blame game between scientists, marketers and regulators.  Full Article